医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cytori Strengthens Global Patent Portfolio

2016年04月18日 PM08:00
このエントリーをはてなブックマークに追加


 

SAN DIEGO

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today a number of key additions to its patent portfolio in Japan and Europe. The company now has 85 global patents issued, 12 of which are in Japan, and another 55 pending around the globe.

The Japanese Patent Office recently granted to Cytori patent No. 5,883,553 which is a foundational patent for the production of cellular and tissue therapeutics containing a combination of adipose tissue with adipose-derived regenerative cells. This patent broadly protects methods for manufacturing therapeutics including those currently being used in Cytori-supported ADRESU phase III urinary incontinence trial in Japan as well as many other indications in the urology, reconstructive and aesthetic markets. This patent protects the Cytori Cell Therapy™ and systems for these applications through at least 2022.

Cytori has also recently strengthened its position in the European market by adding several patents to its existing European portfolio of 8 patents, and by successfully opposing 2 third party European patents related to its core technology.

The European Patent Office granted Patent No. 1921133, which protects current and next generation cellular therapeutic manufacturing technology throughout Europe. The ‘133 patent claims protect Cytori’s technology across all of its clinical indications. Also granted were European Patents No. EP1778293 and EP1776126 that protect cellular therapeutics in the treatment of degenerative disc disease and stroke, respectively.

“Cytori continues to invest in its global IP position, amassing over 85 international patents in strategic markets and countering competitive efforts,” noted John D. Harris, Vice President and General Manager, Cell Therapy. “Japan and Europe are important markets for Cytori and these patents are strategically targeted and will serve to support our efforts in these territories for both current and future applications of our technology.”

About Cytori

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefit across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, statements regarding prosecution, status, benefits and uses of our patent portfolio, are forward-looking statements. These statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical and regulatory uncertainties, the challenges inherent in prosecuting, maintaining and enforcing patent and other intellectual property rights throughout the world, and other risks and uncertainties described under the “Risk Factors” in Cytori’s Securities and Exchange Commission filings, including in its most recent annual and quarterly reports. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this communication to reflect events, trends or circumstances after the date of this communication.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160418005522/en/

CONTACT

Cytori Therapeutics, Inc.
Tiago Girao, +1-858-458-0900
ir@cytori.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果
  • GenePeeks Expands Distribution to India with Exclusive Agreement with CORE Diagnostics